OncoMatch/Clinical Trials/NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Is NCT04196257 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) and BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel for solid tumor, adult.
Treatment: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) · BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel — This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Tumor Agnostic
Ovarian Cancer
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: bone marrow or hematopoietic stem cell transplant
Participants who had previous bone marrow or hematopoietic stem cell transplant
Lab requirements
Blood counts
HgB ≥ 9 g/dL, WBC ≥ 3,000/mcL, ANC ≥ 1,500/mcL, PLT ≥ 100,000/mcL
Kidney function
Serum creatinine < 1.5 x ULN or eGFR > 60 mL/min according to Cockcroft-Gault formula
Liver function
Total bilirubin within normal institutional limits, AST and ALT < 2.5 X institutional ULN
Participants must have adequate: Bone marrow function: HgB ≥ 9 g/dL, WBC ≥ 3,000/mcL, ANC ≥ 1,500/mcL, PLT ≥ 100,000/mcL; Hepatic function: Total bilirubin within normal institutional limits, AST and ALT < 2.5 X institutional ULN; Renal function: Serum creatinine < 1.5 x ULN or eGFR > 60 mL/min according to Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Holy Cross Hospital · Silver Spring, Maryland
- Karmanos Cancer Institute · Detroit, Michigan
- Mary Crowley Cancer Research · Dallas, Texas
- The University of Texas M.D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04196257 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bone marrow or hematopoietic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages